Life sciences company VolitionRx has secured CE mark for its Nu.Q Colorectal Cancer Screening Triage Test paving te way for its launch across the European Union (EU).

Developed in collaboration with the Hvidovre Hospital of University of Copenhagen, Nu.Q detects nucleosomic markers of cancer for an early stage detection using a series of convenient, inexpensive and accurate blood tests.

The test analyses the unique nucleosomes to ascertain the presence of the disease.

"The triage test has exhibited up to 25% efficacy in reducing colonoscopies."

The introduction of the Nu.Q colorectal cancer screening triage test will complement the existing standard screening test, the fecal immunochemical test (FIT) widely used in colorectal cancer screening programmes.

Volition chief marketing and communications officer Louise Day said: "Being able to offer European healthcare systems a simple and easy to use blood test which can be used to triage FIT positive populations for colorectal cancer has the potential to make a significant difference in many people's lives and to help health care systems better serve patients.

“We have identified the first wave of European countries for launch and are pleased with the progress we are making."

The triage test has been designed to identify patients who have received false positive result on their FIT test as the standard test detects blood in stool which is not substantial to confirm presence of cancer.

Application of the triage test determines applicability of colonoscopy for patients on the basis of combined test results which helps streamlining the diagnostic process as well as minimise unnecessary colonoscopies.

The triage test has exhibited up to 25% efficacy in reducing colonoscopies with 97% detection of colorectal cancer when combined with the fecal immunochemical test (FIT) score.